Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study

Affiliations

• ¹ Department of Medicine 3 - Rheumatology and Immunology, Universitatsklinikum Erlangen, Erlangen, Germany. [email protected].
• ² Immunology, Janssen Research & Development, LLC, Spring House, PA, USA.
• ³ Immunology, Janssen Scientific Affairs, LLC, Horsham, PA, USA.
• ⁴ Drexel University College of Medicine, Philadelphia, PA, USA.
• ⁵ Immunology, Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA.
• ⁶ Immunology, Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Issy Les Moulineaux, France.
• ⁷ Immunology, Janssen Medical Affairs, LLC, Zug, Switzerland.
• ⁸ Johnson & Johnson MEA, Dubai, United Arab Emirates.
• ⁹ Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
• ¹⁰ School of Infection and Immunity, University of Glasgow, Glasgow, UK.